Outcomes in UK ACS Patients Prescribed Ticagrelor
Health Outcomes of Patients With Acute Coronary Syndromes Prescribed Ticagrelor in UK Primary Care: a Retrospective Cohort Study
Cohort study using data from Clinical Practice Research Datalink (CPRD). The study cohort includes all patients who received at least one prescription for ticagrelor for the first time between December 2010 and March 2015, following ACS. Patient baseline characteristics will be described: (Age, Gender, Body Mass Index, Smoking status, Sociodemographic status), type of ACS and interventions, CV history and comorbidities, bleeding and respiratory history.
The following outcomes will be examined: Incidence of vascular events (composite MI, Stroke, vascular death, specific vascular event and all cause death), incidence of bleeding and incidence of dysponea. Time to event for vascular events, bleeding and dyspnoea.
Studieoversikt
Status
Status
Forhold
Forhold
Studietype
Studietype
Registrering (Faktiske)
Registrering
Kontakter og plasseringer
Studiesteder
-
-
-
Luton, Storbritannia
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- First prescription (index date) for ticagrelor between Dec 2010 and Mar 2015
- At least 12 months history in database prior to first ticagrelor prescription
- Linkage to Hospital Episode Statistics (HES)
- Acute Coronary Syndrome (ACS) event in the three months prior to and including the index date
Exclusion Criteria:
Primary care prescription for clopidogrel or prasugrel between the ACS date and the index date
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Incidence of composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsramme: From index date up to 12 months
|
From index date up to 12 months
|
|
Incidence of myocardial infarction (MI) in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsramme: From index date up to 12 months
|
From index date up to 12 months
|
|
Incidence of all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsramme: From index date up to 12 months
|
From index date up to 12 months
|
|
Incidence of stroke in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsramme: From index date up to 12 months
|
From index date up to 12 months
|
|
Incidence of vascular death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsramme: From index date up to 12 months
|
From index date up to 12 months
|
|
Time to event for composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsramme: From index date up to 12 months
|
From index date up to 12 months
|
|
Time to event for myocardial infarction (MI) in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsramme: From index date up to 12 months
|
From index date up to 12 months
|
|
Time to event for all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsramme: From index date up to 12 months
|
From index date up to 12 months
|
|
Time to event for stroke in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsramme: From index date up to 12 months
|
From index date up to 12 months
|
|
Time to event for vascular death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsramme: From index date up to 12 months
|
From index date up to 12 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Incidence of bleeding in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsramme: From index date up to 12 months
|
From index date up to 12 months
|
|
Incidence of dyspnoea in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsramme: From index date up to 12 months
|
From index date up to 12 months
|
|
Time to event for bleeding in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsramme: From index date up to 12 months
|
From index date up to 12 months
|
|
Time to event for dyspnoea in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsramme: From index date up to 12 months
|
From index date up to 12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- D5130R00027
- EUPAS17107 (Registeridentifikator: ENCePP)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .